Malle D, Patakiouta F, Bousoulegas A, Karakitsos P, Destouni C
Cytopathology Dept., "Theagenion" Anticancer Hospital, Thessaloniki, Greece.
Eur J Gynaecol Oncol. 2003;24(6):531-4.
To co-evaluate DNA analysis and the expression of c-erb B-2 and p53 oncoproteins with the histologic type and the other known prognostic factors of breast cancer.
Sixty-five imprint smears from breast surgical specimens were examined by immunocytochemical staining for c-erb B-2 and p53 and routine pap staining. The immunostaining was considered positive for c-erb B-2 if the cancer cells showed specific membrane staining and for p53 specific nuclear staining. In 30 breast carcinoma imprints, DNA ploidy was evaluated by an image analysis technique using a SAMBA 2005 analyser.
From the total number of 53 breast carcinomas which were evaluated in our study 25 (47.1%) showed c-erb B-2 immunopositivity, while 16 (30.18%) exhibited p53 positive nuclear immunoreactivity. Ten out of 13 (76.92%) aneuploid breast carcinomas were positive for c-erb B-2 while five out of 13 (38.46%) showed immunopositivity for p53.
From our findings it seems that detection of c-erb B-2 and p53 expression in samples of breast carcinomas could be an important prognostic factor and may identify patients with more aggressive disease.
联合评估DNA分析以及c-erb B-2和p53癌蛋白的表达与乳腺癌的组织学类型及其他已知预后因素。
对65份乳腺手术标本的印片涂片进行c-erb B-2和p53免疫细胞化学染色及常规巴氏染色检查。若癌细胞显示特异性膜染色，则c-erb B-2免疫染色被认为呈阳性；若显示特异性核染色，则p53免疫染色呈阳性。在30份乳腺癌印片中，使用SAMBA 2005分析仪通过图像分析技术评估DNA倍体。
在我们研究中评估的53例乳腺癌总数中，25例（47.1%）显示c-erb B-2免疫阳性，而16例（30.18%）表现出p53阳性核免疫反应性。13例非整倍体乳腺癌中有10例（76.92%）c-erb B-2呈阳性，13例中有5例（38.46%）p53免疫阳性。
从我们的研究结果来看，检测乳腺癌样本中c-erb B-2和p53的表达可能是一个重要的预后因素，并且可能识别出患有侵袭性更强疾病的患者。
